Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Item

http://www.wikidata.org/entity/Q31019795

Q31019795

about

The changing landscape of biosimilars in rheumatology The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used a CT-P13: design, development, and place in therapy Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.The Role of Biosimilars in Inflammatory Bowel Disease.Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product.CT-P13 in the treatment of rheumatoid arthritis.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.Interchangeability of Biosimilars: A European Perspective.Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.Comparative effectiveness of the biosimilar CT-P13.Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.The road from development to approval: evaluating the body of evidence to confirm biosimilarity.Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence.Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.The nocebo effect challenges the non-medical infliximab switch in practice.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis.The biosimilars journey: current status and ongoing challenges A descriptive analysis of real-world treatment patterns of innovator (Remicade) and biosimilar infliximab in an infliximab-naïve Turkish population Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

P2860

Q26766515-CDE75DEB-D6D4-4ED6-BD26-30F59ABE9CDA Q30397234-34CFF84D-F955-4039-A837-EABF7D5C9659 Q31105857-F66EA5BA-64D6-4211-AFA2-D33F98CD628F Q33803728-B552F914-E3BC-403B-AA41-F0ACA580682E Q33840949-B2A48F05-4749-4E20-A981-C61C18404C76 Q33881234-C0CA9587-7E64-41BB-A33F-256F5A7FAB3E Q37453045-02C23BEE-70AC-4638-A864-C1E90213B2B3 Q37540190-68E145FB-112E-4025-B082-6E92277F1988 Q37698663-9064510D-1783-4AE3-89FD-73A3B2BCAB0B Q38676104-2BFDB206-1B34-493E-9F67-0D883FE79623 Q38708927-ED76110B-7724-48DD-B6E2-FABBBC711233 Q38953729-6A499ADB-3A0A-4DC1-B96E-9EED5EC04968 Q39000780-E2D8A07A-8489-4A54-8276-73E51BDC0FB3 Q39184810-6E54F613-C163-4A31-AEF6-4F66873D5F11 Q40233716-C78B7181-C4C9-48A5-B162-191F7C8672A4 Q42360803-3FDEFC1D-7F97-4538-9341-BE09DFBB3647 Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B Q47418286-14B14184-431D-4D4F-BCC7-214B2ED70A10 Q47633961-5A6808C4-A5D7-42C8-9B17-FE49E462571A Q47656264-3A270336-FBDE-44A0-BDBB-65FA15F90AFA Q47688424-8BD7253C-3FBE-4585-B0E2-7B380A96362F Q47807650-A8334686-DCF5-41F0-95AA-3F27EFDD7AFA Q47950956-D32D52C7-E58A-44DE-9060-4C9379AD05B3 Q48092457-A974590D-51FD-4A6D-AA94-FAE2C4DF7314 Q48216426-9C5D9723-7B31-48C2-9BC4-78F750DE4656 Q48309038-F9F1CADE-3376-4221-8FEE-53919227D5CD Q49721192-1EA6C0C0-3668-428F-ABCD-311C6CDD873D Q49979586-D97D6BC0-A0B9-4BD9-A196-DFC4E5CCF523 Q51022840-F6C0F618-6368-4785-8428-4FD6F7793995 Q52651099-B4C6C625-3984-445A-8C38-D6C1A624F79B Q55693631-0A8530CF-F44B-4EC0-9930-2720DC2F04A5 Q57298628-78752546-3B7B-4C46-8553-19748B4BF357 Q57484897-C493055C-18B6-4120-AE86-1CF819A7FBDA Q58795531-C80CB2CF-CC35-4D2C-A248-092982B388DF Q58798380-28866682-FFC4-49A7-AC72-44D82EC10060

P2860

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Item

http://www.wikidata.org/entity/Q31019795

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu